Zenas Biopharma (ZBIO) & The Competition Head-To-Head Survey

Zenas Biopharma (NASDAQ:ZBIO) is one of 422 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Zenas Biopharma to similar companies based on the strength of its risk, profitability, institutional ownership, valuation, analyst recommendations, earnings and dividends.

Profitability

This table compares Zenas Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas Biopharma	N/A	N/A	N/A
Zenas Biopharma Competitors	-14,682.20%	39.10%	-32.41%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Zenas Biopharma and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas Biopharma	0	0	2	0	3.00
Zenas Biopharma Competitors	831	2270	4732	56	2.51

Zenas Biopharma currently has a consensus target price of $40.00, suggesting a potential upside of 418.81%. As a group, “Biotechnology” companies have a potential upside of 50.86%. Given Zenas Biopharma’s stronger consensus rating and higher probable upside, equities analysts clearly believe Zenas Biopharma is more favorable than its rivals.

Dividends

Zenas Biopharma pays an annual dividend of $0.05 per share and has a dividend yield of 0.6%. Zenas Biopharma pays out -1.4% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 4.5% and pay out 116.1% of their earnings in the form of a dividend.

Valuation and Earnings

This table compares Zenas Biopharma and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zenas Biopharma	$5.00 million	N/A	-2.17
Zenas Biopharma Competitors	$154.14 million	-$11.26 million	-61.28

Zenas Biopharma’s rivals have higher revenue, but lower earnings than Zenas Biopharma. Zenas Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

29.3% of shares of all “Biotechnology” companies are held by institutional investors. 22.5% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Zenas Biopharma beats its rivals on 7 of the 13 factors compared.

Zenas Biopharma Company Profile

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.